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UTILIZING LIPOPOLYSACCHARIDE IN 
EXHALED BREATH CONDENSATE TO 
DIAGNOSE GRAM NEGATIVE PNEUMONIA 
CROSS-REFERENCE TO RELATED 
APPLICATION 
2 
In general, features such as the patient's complaint, the 
patient's vital signs, the peripheral white blood count, and the 
results of chest radiography are used to determine the pres-
ence or absence of pneumonia. When these sources of data fit 
a typical pattern, the diagnosis can be made with reasonable 
clinical certainty, and antimicrobial therapy can be initiated 
prior to the results of bacteriological cultures. Although non-
specific clinical data is often used to initiate antibiotic treat-
ment for Gram negative infection, common practice dictates 
This application claims the benefit of, and claims priority 
to provisional U.S. Patent Application Ser. No. 60/577,641, 
filed on Jun. 7, 2004, which is incorporated herein by refer-
ence in its entirety. 
This application is also a continuation-in-part of U.S. 
patent application Ser. No. 10/742,721 filed Dec. 19, 2003, 
which claims the benefit of provisional U.S. Patent Applica-
tion Ser. No. 60/434,916 filed Dec. 20, 2002 and provisional 
U.S. Patent Application Ser. No. 60/447,581 filed Feb. 14, 
2003. The entirety of each of the aforementioned applications 
is incorporated herein by reference. 
10 that the final diagnosis of Gram negative pneumonia requires 
more specific evidence of Gram negative bacterial lung infec-
tion. 
Toward this goal, a Gram's stain can be performed imme-
diately on sputum that is coughed from the lower airways, and 
In addition, this is a continuation-in-part of U.S. patent 
application Ser. No. 10/778,477 filed Feb. 13, 2004, which 
claims the benefit of provisional U.S. Patent Application Ser. 
No. 60/447,581filedFeb.14,2003. Theentiretyofeachofthe 
aforementioned applications is likewise incorporated herein 
by reference. 
15 microscopic analysis may reveal bacteria with morphology 
and color suggesting Gram negative infection. However, use-
ful sputum samples are notoriously difficult to obtain from 
humans with pneumonia. When blood specimen cultures 
from a patient who has a clinical pattern consistent with 
20 pneumonia grow a Gram negative bacterium, this provides a 
specific indication of Gram negative pneumonia. Unfortu-
nately, more often than not, the blood is sterile in a patient 
with Gram negative pneumonia. 
In addition, a patient's blood may be examined for endot-
BACKGROUND OF THE PRESENT INVENTION 
1. Field of the Present Invention 
The present invention relates generally to a method and 
devices for diagnosing gram negative bacterial pneumonia 
and, in particular, to diagnosing gram negative bacterial pneu-
monia by detecting the presence of lipopolysaccharide in 
exhaled breath condensate. 
25 oxin concentration using chemical assays for the endotoxin 
molecule. However, endotoxin concentrations have been 
found to be an inaccurate predictor of either the cause or 
severity of the more general sepsis syndrome. Endotoxin 
concentrations in the blood may fluctuate widely over short 
2. Background 
30 time periods. Further, certain disease states, including liver 
disease, polytrauma, hypertension, and hematological malig-
nancies are associated with chronically elevated endotoxin 
concentrations in the absence of clinically significant infec-
tion. No study has examined whether circulating endotoxin 
Pneumonia represents a common disease with significant 
morbidity and mortality. Pneumonia is the number one cause 
35 concentrations can predict a gram negative source of pneu-
of death by infectious disease and the sixth most common 
cause of death in the United States. The National Hospital 
Ambulatory Medical Care Survey found that in 2001, 1.48 
million emergency department visits were related to a diag- 40 
no sis of pneumonia The National Hospital Discharge Survey 
found that in 1998, 1.32 million patients were discharged 
after having been treated for pneumonia. 
Pneumonia can be caused by lung infection of many types 
of microorganisms, including viruses, chlamydia, myco- 45 
plasma, protozoa, fungi, and bacteria. For a patient with sus-
pected pneumonia, the clinician has a duty to determine the 
exact cause of infection because the identity of the infectious 
agent dictates the choice of antimicrobial treatment. The most 
common cause in Western society is bacterial pneumonia, and 50 
when bacterial pneumonia is suspected, clinicians generally 
seek to categorize the cause of bacterial pneumonia as Gram 
positive, Gram negative or anaerobic. 
In particular, clinicians are motivated to identify the pres-
ence of Gram negative bacterial infection because Gram 55 
negative lung infections are aggressive and are associated 
with higher rates of complications and death. The Gram nega-
tive feature of bacteria refers to the color of the bacteria after 
mama. 
A sensitive and specific method to diagnose Gram negative 
lung infection is to perform bronchalveolar lavage and to 
perform a bacteriological culture on the lavage fluid. Another 
method is to chemically assay for lipopolysaccharide content 
in bronchoalveolar lavage samples. Investigators using this 
method found that high concentrations oflipopolysaccharide 
are associated with concomitant growth of grain negative 
bacteria in cultures of the bronchalveolar fluid. A complete 
description of this method may be found in Flanagan, P. G., 
Jackson, S. K., Findlay, G., "Diagnosis of Gram negative, 
ventilator associated pneumonia by assaying endotoxin in 
bronchial lavage fluid", J. Clin. Pathol. 2001, 54: 107-110 and 
Pugin, J., Auckenthaler, R. and Delaspre, 0., "Rapid Diag-
nosis of gram-negative pneumonia by assay of endotoxin in 
bronchoalveolar lavage fluid", Thorax 1992, 47:547-549. 
Both methods have the drawbacks that special endoscopic 
equipment and subspecialty expertise are required and that 
they are relatively invasive and uncomfortable procedures. 
Moreover, known culture methods require at least 24 hours to 
obtain results.As such, a patient may wait for up to at least 24 
hours before receiving an effective antibiotic treatment. 
The cell wall of Gram negative bacteria comprises endot-
oxins. Endotoxins are toxic materials released by bacterium 
on bacterial lysis. While endotoxins were first recognized for 
their ability to induce fever, they are now known to have a 
broad spectrum of biologic activities. On bacteriolysis, 
endotoxins consisting of aggregates of lipopolysaccharides 
and protein and lipids, are released from the bacterium into 
a staining protocol that will be well understood by those 
skilled in the art. Gram negative bacterial infections, includ- 60 
ing gram negative bacterial pneumonia, require specific anti-
microbial therapy, which is different from treatment for other 
types of bacterial infections, and warrant an elevated level of 
financial reimbursement from third party payors such as 
Medicare. 65 surrounding medium Endotoxins consist primarily of 
lipopolysaccharide ("LPS") with various amounts of protein 
and lipid. Since almost all of the biologic activities usually 
In current clinical practice, pneumonia is diagnosed by 
combining clinical, laboratory and radiographic information. 
US 7,828,741 B2 
3 
attributable to bacterial endotoxins can also be elicited with 
isolated chemically pure lipopolysaccharide, the terms 
"endotoxin" and "lipopolysaccharide" are used interchange-
ably. 
From a pathogenic standpoint, the presence oflipopolysac-
charide is one of the most important implications of a Gram 
negative infection. As such, detecting lipopolysaccharide in a 
patient's bodily fluid is an indicator of Gram negative bacte-
rial infection. More specifically, the presence oflipopolysac-
charide in a patient's bodily fluid is an important potential 
indicator of Gram negative pneumonia. 
The present invention overcomes the above-described 
clinical disadvantages of diagnosing Gram negative bacterial 
pneumonia by performing an assay for lipopolysaccharide on 
the liquid derived from condensation of exhaled breath.Using 
novel devices and methods described herein, exhaled breath 
condensate may be obtained from a spontaneously breathing 
subject via a mouthpiece, facemask or other similar means or 
from a subject breathing with the assistance of a mechanical 
ventilator via a connection to the expiratory tubing of the 
mechanical ventilator. An additional advantage of the present 
invention is the shorter time period for diagnosing a Gram 
negative bacterial infection, such as pneumonia, than is 
required for other diagnostic methods. 
4 
method further includes selecting an antibiotic therapy in 
response to a positive determination that the subject has an 
intrapulmonary Gram negative bacterial infection; collecting 
exhaled breath condensate from an air-breathing vertebrate 
subject includes collecting exhaled breath condensate from a 
mammalian subject, and the method further includes moni-
toring the response of the mammalian subject to antibiotic 
therapy; the method further includes identifying the particu-
lar strain of the intrapulmonary Gram negative bacteria; iden-
10 tifying includes identifying the particular strain of intrapul-
monary Gram negative bacteria based upon a determination 
of the 0-saccharide portion of the lipopolysaccharide mol-
ecule; measuring the concentration of lipopolysaccharide 
includes measuring the concentration of lipopolysaccharide 
15 using the limulus amoebocyte lysate assay; a measured con-
centration oflipopolysaccharide of at least about 0.20 Endot-
oxin Units/mL (EU/mL) indicates the presence of a Gram 
negative bacterial infection; collecting exhaled breath con-
densate from an air-breathing vertebrate subject includes col-
20 lecting the expired breath condensate from a spontaneously 
breathing subject; collecting exhaled breath condensate from 
an air-breathing vertebrate subject includes collecting the 
expired breath condensate from a mechanically ventilated 
subject; and collecting exhaled breath condensate from an 
25 air-breathing vertebrate subject includes utilizing an exhaled 
breath condensate collection device comprising a chamber 
having inner walls that may be cooled to a temperature of 
about 32 degrees Fahrenheit and below to promote conden-
sation. 
Alternative devices for collecting exhaled breath conden-
sate are also known. These devices include those disclosed in 
Gaston et al., U.S. Pat. Nos. 6,033,368 and 6,419,634; Hunt et 
al., U.S. Pat. No. 6,585,661; Baddour, U.S. application Ser. 
No.10/257,912; and EU Patent No. 0,759,169Bl to Winselet 
al., all of which are incorporated by reference herein in their 30 
entireties. In addition, Kline, U.S. application Ser. Nos. 
10/742,721 and 10/778,477, two commonly-assigned non-
provisional patent applications, disclose devices for collect-
ing exhaled breath and are incorporated by reference herein in 
their entireties. 
The present invention, according to another aspect, is a 
method for diagnosing and monitoring intrapulmonary Gram 
negative bacterial infection in an air-breathing vertebrate sub-
ject, including: collecting exhaled breath condensate from an 
air-breathing vertebrate subject; providing a reaction cham-
35 ber, wherein said reaction chamber has a reaction reagent 
disposed therein; delivering at least a portion of the collected 
exhaled breath condensate to the reaction chamber; and deter-
mining whether the subject has an intrapulmonary Gram 
Exhaled condensate is known to contain many molecules 
that can serve as markers of many lung diseases, as reviewed 
by Kharitinov et al. in 2001 (Biomarkers 7 (1): 1-32, 2002.). 
However, the concept of measuring lipopolysaccharide in 
exhaled breath condensate for the purpose of diagnosing 40 
Gram negative pneumonia or other Gram negative bacterial 
infections has not been disclosed previously. 
negative bacterial infection based on a physical change that 
occurs when the at least a portion of the collected exhaled 
breath condensate is delivered to the reaction chamber, 
wherein said physical change is caused by the presence of 
lipopolysaccharide in the exhaled breath condensate. 
SUMMARY OF THE PRESENT INVENTION 
The present invention comprises a method for determining 
whether a subject has Gram negative bacterial pneumonia 
based on the presence oflipopolysaccharide in exhaled breath 
condensate collected from the subject. The present invention 
further comprises the collection devices utilized to collect 
exhaled breath condensate from both spontaneously breath-
ing and mechanically ventilated subjects and the devices uti-
lized to determine whether lipopolysaccharide is present in 
the collected exhaled breath condensate. 
Broadly defined, the present invention, according to one 
aspect, is a method for diagnosing and monitoring intrapul-
monary Gram negative bacterial infection in an air-breathing 
vertebrate subject, including: collecting exhaled breath con-
densate from an air-breathing vertebrate subject; measuring 
the concentration of lipopolysaccharide in the collected 
exhaled breath condensate; and determining whether the sub-
ject has an intrapulmonary Gram negative bacterial infection 
based on the measured concentration oflipopolysaccharide in 
the exhaled breath condensate. 
In features of this aspect, the intrapulmonary Gram nega-
tive bacterial infection is pneumonia; the intrapulmonary 
Gram negative bacterial infection is a bronchial infection; the 
In features of this aspect, the reaction reagent includes a 
45 limulus amoebocyte lysate, a chromogenic substrate and/or a 
fluorogenic substrate; the reaction reagent includes a chemi-
cal that liberates heat through an exothermic reaction upon 
delivery of the at least a portion of the exhaled breath con-
densate; the physical change is the formation of a gel; the 
50 method further includes visually matching a color change in 
the reaction chamber to a standard, wherein said standard 
comprises a printed strip of color patches of increasing hue 
intensity, and wherein each color patch corresponds to 
increasing concentrations of lipopolysaccharide, respec-
55 tively; a hue intensity corresponding to a concentration of0.2 
endotoxin units per milliliter indicates the presence of an 
intrapulmonary Gram negative bacterial infection; collecting 
exhaled breath condensate from an air-breathing vertebrate 
subject includes collecting the expired breath condensate 
60 from a spontaneously breathing subject; collecting exhaled 
breath condensate from an air-breathing vertebrate subject 
includes collecting the expired breath condensate from a 
mechanically ventilated subject; collecting exhaled breath 
condensate from an air-breathing vertebrate subject includes 
65 utilizing an exhaled breath condensate collection device com-
prising a chamber having inner walls that may be cooled to a 
temperature of about 32 degrees Fahrenheit and below to 
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promote condensation; and delivering at least a portion of the 
exhaled breath condensate comprises injecting at least of 
portion of the exhaled breath condensate into the reaction 
chamber via a hypodermic needle. 
The present invention, according to another aspect, is a 
method for diagnosing and monitoring intrapulmonary Gram 
negative bacterial infection in an air-breathing vertebrate sub-
ject, including: collecting exhaled breath condensate from an 
air-breathing vertebrate subject; providing a reaction cham-
ber with an interior surface, wherein said reaction chamber 10 
has a material that binds lipopolysaccharide disposed therein; 
delivering at least a portion of the collected breath condensate 
6 
one side thereof for measuring hydraulic pressure; and the 
narrow tube is a hypodermic needle disposed at the end of the 
syringe. 
The present invention, according to another aspect, is a 
device for collecting exhaled breath condensate from a sub-
ject breathing with the assistance of a mechanical ventilation 
circuit, including: a mechanical ventilation circuit for facili-
tating breathing of the subject, wherein the mechanical ven-
tilation circuit includes an expiratory flow tube that serves as 
a conduit for removing exhaled breath of the subject; a central 
chamber having an interior, wherein said central chamber 
may be cooled to a temperature of about 32 degrees Fahren-
heit and below to promote condensation; a breath input 
assembly, disposed at one end of the central chamber, in fluid 
communication with the interior of the central chamber and 
the expiratory flow tube, whereby the breath input assembly 
connects the expiratory flow tube and the central chamber; an 
exit assembly, disposed at the other end of the central cham-
ber, in fluid communication with the interior of the central 
to the reaction chamber; washing the reaction chamber with a 
buffer; delivering a reaction reagent to the reaction chamber; 
and determining whether the subject has an intrapulmonary 15 
Gram negative bacterial infection based on a physical change 
that occurs when the at least a portion of the collected exhaled 
breath condensate is delivered to the reaction chamber, 
wherein said physical change is caused by the presence of 
lipopolysaccharide in the exhaled breath condensate. 
In features of this aspect, the reaction reagent comprises a 
chromogenic substrate and/or a fluorogenic substrate; the 
binding material is an antibody that binds a specific species of 
lipopolysaccharide; the antibody is disposed on the interior 
surface of the reaction chamber; the binding material is an 25 
insoluble polymer; the binding material is embedded in a 
matrix surface disposed within the reaction chamber; the 
method further includes visually matching a color change in 
the reaction chamber to a standard, wherein said standard 
comprises a printed strip of color patches of increasing hue 30 
intensity, and wherein each color patch corresponds to 
increasing concentrations of lipopolysaccharide, respec-
tively; a hue -intensity corresponding to a concentration of 0.2 
endotoxin units per milliliter indicates the presence of an 
intrapulmonary Gram negative bacterial infection; collecting 35 
exhaled breath condensate from an air-breathing vertebrate 
subject includes collecting the expired breath condensate 
from a spontaneously breathing subject; collecting exhaled 
breath condensate from an air-breathing vertebrate subject 
includes collecting the expired breath condensate from a 40 
mechanically ventilated subject; collecting exhaled breath 
condensate from an air-breathing vertebrate subject includes 
utilizing an exhaled breath condensate collection device com-
prising a chamber having inner walls that may be cooled to a 
temperature of about 32 degrees Fahrenheit and below to 45 
promote condensation; delivering at least a portion of the 
exhaled breath condensate comprises injecting at least of 
portion of the exhaled breath condensate into the reaction 
chamber via a hypodermic needle. 
20 chamber; and a vacuum device connected to the exit assembly 
for collecting exhaled breath condensate from the central 
chamber. 
The present invention, according to another aspect, is a 50 
method for diagnosing and monitoring intrapulmonary Gram 
negative bacterial infection in an air-breathing vertebrate sub-
ject, including: collecting exhaled breath condensate from an 
air-breathing vertebrate subject in a collection device having 
a narrow tube; inserting a fibrous plug impregnated with 55 
enzymes that cause gelation upon exposure to lipopolysac-
charide into the narrow tube; introducing at least a portion of 
the collected exhaled breath condensate sample into the nar-
row tube to wet the fibrous plug; and determining whether the 
subject has an intrapulmonary Gram negative bacterial infec- 60 
ti on based on the amount of gelation that occurs in the narrow 
tube, wherein said gelation is caused by the presence of 
lipopolysaccharide in the exhaled breath condensate. 
In features of this aspect, the fibrous plug is impregnated 
with enzymes from limulus amoebocyte lysate; the method 65 
further includes providing a syringe disposed within the col-
lection device, said syringe having a manometer disposed on 
The present invention, according to another aspect, is a 
breath condensate collection device, including: a central 
chamber having an interior and first and second opposing 
ends; a breath input assembly in fluid communication with 
the interior of the central chamber; and an exit assembly in 
fluid communication with the interior of the central chamber, 
wherein the exit assembly includes a narrow tube, said narrow 
tube having a fibrous plug disposed therein, said plug being 
impregnated with a reaction reagent that causes gelation upon 
exposure to lipopolysaccharide. 
In features ofthis aspect, the plug is a fiber matrix impreg-
nated with enzymes from a limulus amoebocyte; and the 
device further includes a plunger assembly having a piston 
and a handle, wherein the piston is slidably disposed in the 
interior of the central chamber and wherein the handle 
extends from the first end of the central chamber so as to 
permit the piston to be moved within the central chamber, 
whereby the collected breath condensate may contact the 
fibrous plug disposed within the narrow tube. 
The present invention, according to another aspect, is a 
reaction chamber assembly for measuring the concentration 
of lipopolysaccharide in exhaled breath condensate, includ-
ing: a reaction chamber; a delivery port for delivery of the 
exhaled breath condensate into the reaction chamber; a reac-
tion reagent to react with lipopolysaccharide present in the 
exhaled breath condensate; and a viewing portion to allow for 
visible detection of a physical change in the reaction chamber. 
In features of this aspect, the delivery port is a re-sealable 
cover that may be punctured with a hypodermic needle for 
delivery of the exhaled breath condensate; the viewing por-
tion is a transparent wall; the reaction chamber further 
includes an interior surface, and a lipopolysaccharide-immo-
bilizing agent is bound to at least a portion of the interior 
surface of the reaction chamber; the lipopolysaccharide-im-
mobilizing agent is selected from the group consisting of 
monoclonal antibodies, polyclonal antibodies, polymyxin 
antibiotic, lipopolysaccharide-binding protein and limulus 
anti-lipopolysaccharide factor; the reaction chamber further 
includes a chemical disposed within the reaction chamber, 
wherein the chemical liberates heat upon hydration, whereby 
a temperature in the range of 34 to 43 degrees Celsius is 
achieved for a period of 15 to 30 minutes upon hydration of 
the chemical; the chemical is a salt in a semipermeable 
matrix; the chemical is a salt in crystalline form; and the 
chemical is sodium thiosulfate pentahydrate. 
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The present invention, according to another aspect, is a test 
kit cartridge for detecting the presence of lipopolysaccharide 
in exhaled breath condensate, including: a housing; a test 
module disposed within the housing, said test module utiliz-
ing a user-initiated chemical reaction to detect the presence of 
lipopolysaccharide in the exhaled breath condensate; and a 
positive control module disposed within the housing adjacent 
to the test module, said positive control module having 
lipopolysaccharide disposed therein for showing a definite 
positive result for the presence of lipopolysaccharide for 10 
comparison with the test module. 
In features of this aspect, a chemical disposed in the hous-
ing provides a controlled exothermic reaction, whereby a 
temperature between 34 and 43 degrees Celsius is achieved 
for a period of 15 to 30 minutes; the chemical is sodium 15 
thiosulfate pentahydrate; each module of the test kit includes 
a re-sealable injection port, a reaction well, a fluid connection 
between the reaction well and the injection port, a first one-
way valve disposed in the fluid connection, an exit tube pro-
viding an outlet for the reaction well, and a second one-way 20 
valve disposed in the exit tube; each reaction well includes a 
clear covering adapted to allow visual determination of physi-
8 
FIG. 7 is a side cross-sectional schematic view of a reaction 
chamber device suitable for use with the collection devices of 
FIGS. 2, 4 and 5; 
FIG. 8 is a top view of the reaction chamber device of FIG. 
7; 
FIG. 9 is a side perspective view of a first alternative 
reaction chamber device; 
FIGS. lOA-lOD are partial side cross-sectional views of 
the first alternative reaction chamber device of FIG. 9; 
FIG. 11 is a perspective view of a test kit incorporating a 
second alternative reaction chamber device; 
FIG. 12 is a side cross-sectional view of the test module of 
FIG. 11, taken along line 12-12; 
FIG.13 is a side cross-sectional view of the positive control 
module of FIG. 11, taken along line 13-13; 
FIG. 14 is a partial side cross-sectional view of a breath 
condensate collection device in accordance with a fourth 
preferred embodiment of the present invention; 
FIG. 15 is an enlarged partial side cross-sectional view of 
the needle of FIG. 14; and 
FIG. 16 is a scatter plot graph illustrating the measured 
endotoxin concentrations for patients in each of three study 
groups. 
DETAILED DESCRIPTION OF THE PREFERRED 
EMBODIMENTS 
cal change; each reaction well includes an insoluble poly-
meric lipopolysaccharide-binding matrix; the positive con-
trol module reaction well includes lipopolysaccharide from a 25 
suitable species of Gram negative bacteria; the test kit car-
tridge further includes a chromogenic substrate, reconstituted 
from a reaction chamber; the test kit cartridge further includes The method of the present invention utilizes exhaled breath 
condensate to determine whether LPS is present in the 
30 exhaled breath condensate and thus determine whether a sub-
a color strip, the color strip having color patches ofincremen-
tally increasing color intensity, wherein each color patch cor-
responds to a prescribed range of endotoxin units to allow for 
visual comparison against a color change in the reaction 
wells; the housing is formed from a polymer; the polymer is 
plastic. 
ject has an intrapulmonary Gram negative bacterial infection. 
The present application is directed toward diagnosing Gram 
negative bacterial pneumonia; however, one of ordinary skill 
in the art will understand that the present invention may be 
Further areas of applicability of the present invention will 35 
become apparent from the detailed description provided here-
inafter. It should be understood that the detailed description 
and specific examples, while indicating the preferred embodi-
ment of the invention, are intended for purposes ofillustration 
only and are not intended to limit the scope of the invention. 40 
utilized to detect any Gram negative bacterial infection, 
which is also useful. A patient diagnosed with a Gram nega-
tive bacterial infection will be treated with the same antimi-
crobial therapy whether the diagnosis is Gram negative pneu-
monia or another Gram negative bacterial infection. One of 
ordinary skill in the art will understand that while the meth-
odology for detecting LPS, as described herein, is the limulus 
amoebocyte lysate assay, any methodology for detecting the 
presence of LPS, including, but not limited to the ELISA 
assay and the rabbit pyrogen test, may be utilized in the 
BRIEF DESCRIPTION OF THE DRAWINGS 
Further features, embodiments, and advantages of the 
present invention will become apparent from the following 45 
detailed description with reference to the drawings, wherein: 
present invention. 
Intrapulmonary LPS content can vary based upon the 
health of the lung in the subject providing a breath condensate 
sample. Generally, a concentration of LPS in exhaled breath 
condensate of at least about 0.2 EU/mL corresponds to a 
FIG. 1 is a schematic diagram of the basic structure of 
lipopolysaccharide; 
FIG. 2 is a side cross-sectional schematic view of a breath 
condensate collection device in accordance with a first pre-
ferred embodiment of the present invention; 
FIG. 3A is a partial side cross-sectional schematic view of 
the breath condensate collection device of FIG. 2 with the 
plunger assembly in a partially depressed position; 
FIG. 3B is a partial side cross-sectional schematic view of 
the breath condensate collection device of FIG. 2 with the 
plunger assembly in a fully depressed position; 
FIG. 4 is a partial side cross-sectional view of a breath 
condensate collection device in accordance with a second 
preferred embodiment of the present invention; 
FIG. 5 is a side cross-sectional schematic view of a breath 
condensate collection device in accordance with a third pre-
ferred embodiment of the present invention; 
FIG. 6 is a schematic illustration of an alternative ventila-
tion system implementation of the preferred embodiments of 
the present invention; 
50 clinical test positive threshold, indicating the presence of 
Gram negative bacterial infection in the lungs. An EU is an 
endotoxin unit. The USDA recommends reporting the con-
centration of endotoxin in endotoxin units because an EU can 
be standardized, unlike typical mass concentrations, which 
55 cannot be standardized because of the variable potency of 
lipopolysaccharide, which varies between bacteria type. An 
endotoxin unit refers to the amount of LPS reactivity con-
tained in the unknown sample. This amount of reactivity is 
determined by interpolation from a standard curve, which is 
60 derived from an FDA-approved strain of E-Coli that has a 
known amount ofLPS reactivity. 
It is possible for the device used to collect exhaled breath 
condensate to contain a "background" level of LPS due to 
naturally occurring LPS. In order to account for this back-
65 ground concentration, a "mock" standard may be conducted 
with the device that will be used for exhaled breath collection 
by instilling LPS-free water through the device. The LPS 
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concentration values found in the water sample may then be 
subtracted from the LPS concentration values found in breath 
condensate samples to remove the background "noise" of the 
system. The background concentration of LPS will vary 
depending on the device being used for collection. 
10 
buffer must be present to maintain a pH between 6.5 and 7.4, 
enabling the clotting enzyme to function. 
Various techniques have been utilized to detect LPS based 
on the formation of a coagulen gel in the LAL assay. Some are 
endpoint assays that simply wait for the formation of a gel to 
determine the presence ofLPS. Others are more complex and 
use kinetic turbidimetric methods to measure the increase in 
turbidity as coagulation occurs in the LAL assay. 
An alternative assay methodology using chromogenic or 
A breath condensate collection device, several examples of 
which are described herein below in further detail, may be 
used to collect exhaled breath condensate from a patient 
presenting symptoms synonymous with Gram negative bac-
terial pneumonia for detection of LPS content in amounts 
indicating infection. 
Referring now to the drawings, in which like numerals 
represent like components throughout the several views, the 
preferred embodiments of the present invention are next 
described. The following description of the preferred 
embodiment( s) is merely exemplary in nature and is in no 
way intended to limit the invention, its application, or uses. 
10 fluorogenic substrates has also been used to detect LPS in 
order to overcome difficulties associated with accurately 
determining gel formation. This alternative methodology 
relies on the clotting enzyme that was formed in the above 
cascade reaction hydrolyzing an amide bond in a synthetic 
FIG. 1 is a schematic diagram of the basic structure of 
lipopolysaccharide. This structure is found in the cell wall of 
all Gram negative bacteria. Lipopolysaccharide (also referred 
to as endotoxin) is a complex glycolipid, weighing approxi-
mately 10 Kd. The basic structure of lipopolysaccharide 
involves three relatively well defined regions and is similar in 
15 substrate. The synthetic substrate may be covalently attached 
to a marker molecule or compound, which is liberated when 
hydrolyzed by the clotting enzyme. The liberated marker may 
then be detected by colorimetry or spectrophotometry, thus 
indicating the presence of LPS. Examples of synthetic sub-
20 strates may include, but are not limited, t-butoxycarbonyl-
leucyl-glycyl-arginine-paranitroanilide (N-t-Boc-Leu-Gly-
Arg-pNA), N-t-Boc-Val-Leu-Gly-Arg-pNA (SEQ ID NO: 1), 
benzyloxycarbony 1-leucy 1-glycy 1-arginine-paranitroanilide 
(Z-Leu-Gly-Arg-pNA), Boc-Ile-Glu-Gly-Arg-pNA (SEQ ID all gram-negative bacteria. These regions are an 0-antigen 
portion, a core polysaccharide and lipid A. The 0-antigen 
portion is composed of repeating polysaccharide units, each 
having 2-6 saccharides. The 0-antigen portion varies consid-
erably among Gram negative species and can thus serve as a 
marker of individual bacterial species, based upon binding of 
specific monoclonal antibodies. The core lies between the 
0-antigen portion and lipid A and is a branching polysaccha-
ride having representative sugars such as glucose, N-acetyl-
glucosamine and galactose. Unlike the 0-antigen portion, 
there is only minor variation throughout the core region with 
the structure being highly conserved in the inner core region 35 
proximal to lipid A. The most highly conserved portion of the 
LPS molecule is lipidA, a disaccharide di phosphate, to which 
long-chain fatty acids are attached. The lipid A portion of the 
molecule confers toxicity in virtually all complex eukariotic 
organisms. In humans, this includes induction of cytokines, 40 
fever, leukocytosis, recruitment and activation ofleukocytes, 
vascular damage, vasodilation, intravascular coagulation and 
organ damage. 
25 NO: 2), Boc-Val-Ser-Gly-Arg-pNA (SEQ ID NO: 3) or Boc-
Ser-Gly-Arg-pNA, all of which liberate paranitroaniline, 
which imparts a yellow color to the reaction mixture. Specific 
examples of chromogenic assays are described in Ling, U.S. 
Pat. No. 6,645,724, and Tamura et al., U.S. Pat. No. 5,702, 
30 882. 
It is also possible to synthesize the enzyme needed for the 
clotting cascade in-vitro by recombinant biotechnology 
rather than obtaining the enzyme from a horseshoe crab. Such 
synthesized enzyme can be used to detect and quantify LPS in 
an unknown solution using the chromogenic method. 
Other alternate methods of capturing and detecting LPS are 
also known. An LPS binding material, e.g., polymyxin anti-
biotics or resins, in the form of an insoluble matrix polymer, 
may be affixed to a support for immobilization and subse-
quent detection ofLPS by any of the above described turbi-
dimetric, chromogenic or fluorogenic methods. In addition, 
One accepted method of detecting and quantifying LPS 
takes advantage of the toxic effect of LPS on the aqueous 45 
extract of amoebocytes from the horsehoe crab, limulus 
polyphemus. The term "amoebocytes," as used in the present 
application, refers to blood cells. This method, known gener-
ally as the limulus amoebocyte lysate ("LAL") assay, is 
described in U.S. Pat. Nos. 4,322,217; 5,310,657 and 5,702, 50 
882. Other recognized methods include the in-vivo rabbit 
pyrogen assay and the human pyrogen assay, which are well 
known to those skilled in the art and thus, will not be dis-
cussed in detail herein. 
LPS may be immobilized by any number of antibodies with a 
high affinity for LPS. Antibodies have a Y-shaped structure 
and include two basic units. The first unit is the fragment-
antigen binding portion ("Fab") and it binds an antigen, in this 
situation, LPS. The second unit is the fragment-crystallized 
portion ("Fe"). The Fe unit can function as a handle to dock 
the antibody to an immobile surface. Potentially useful anti-
bodies include, but are not limited to, polyclonal or mono-
clonal antibodies, such as lipid-A reactive monoclonal anti-
body ("HA-IA") and murine anti-endotoxin 
immunoglobulin M ("E5"), lipopolysaccharide-binding pro-
tein ("LBP") and related proteins, bacteriocidal/permeability 
increasing protein ("BPI") and limulus anti-LPS factor 
Briefly summarized, LAL forms a coagulen gel when incu-
bated with LPS, which enables the detection of small quan-
tities ofLPS. More specifically, in the LAL assay, LPS acti-
vates an enzyme, commonly known as factor C, which is 
contained in the amoebocytes. Activated factor C, in tum, 
activates factor B by hydrolyzing a specific site of factor B. 
Activated factor B activates a proclotting enzyme to convert it 
into a clotting enzyme. The clotting enzyme then cleaves 
coagulogen (coagulant protein, molecular weight: 19, 723) at 
specific sites (i.e., Arg8 -Thr19 andArg46-Gly47) to cause gela-
tion of the mixture. In addition, co-factors such as salts of 
calcium, magnesium and phosphate or other organic com-
pounds such as hydroxymethyl ("TRIS") aminomethane 
55 ("LALF"). 
A method utilizing enzyme-linked immunoassay technol-
ogy is also known in which various selected matrix-bound 
antibodies may be used to capture and detect specific endot-
oxins and therefore specific bacteria types. Examples of 
60 endotoxin from bacteria that may be detected, include, but are 
not limited to, Escherichia, Bordetilla, Branhamella, Salmo-
nella, Haemophilus, Klebsiella, Proteus, Enterobacter, 
Pseudomonas, Pasteurella, Acinetrobacter, Chlamydia and 
Neisseria and in general any bacteria whose LPS is capable of 
65 binding to the selected antibody. 
It is further recognized that the presence of ~-1,3 glucans 
(~-D-glucans) may also activate the above-described clotting 
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cascade. One of ordinary skill in the art will understand that 
specific measures may be undertaken to limit this false posi-
tive effect. 
The present invention includes several collection devices 
designed to allow rapid (e.g., less than 30 minutes), noninva-
sive collection of exhaled breath condensate ("EBC") from a 
spontaneously breathing subject or a patient receiving 
mechanical ventilation, followed by one-step quantitative or 
semi-quantitative analysis of the condensate for the concen-
tration of LPS. In spontaneously breathing subjects, the 10 
exhaled condensate may generally be collected via a mouth-
piece held by the lips; however, in patients with severe respi-
ratory distress, the sample may be collected by fitting the 
patient with an airtight, snug-fitting facemask that allows the 
delivery of oxygen, while allowing the diversion of exhaled 15 
gases and aerosol into a condensing chamber such as those 
described below. 
12 
plastic or another deformable polymer. The design of such 
valves would be apparent to those of ordinary skill in the art. 
The piston 26 includes a tip or protrusion 27 of dimensions 
and shape suitable for fitting snugly into the nozzle 39 when 
the plunger assembly 25 is fully depressed. The tip 27 
includes a plurality of radial conduits 31 arranged around the 
base of the tip 27 and connecting to a hollow central shaft or 
conduit 33 in which is disposed a needle 35, such as a hypo-
dermic needle. The radial conduits 31 and the central conduit 
33 are preferably between about 1 and 2 mm in diameter, and 
the outside diameter of the needle 35 is likewise preferably 
between about 1 and 2 mm in diameter in order to fit snugly 
into the central conduit 33. 
Further, because the piston 26 fills one end of the syringe 
20 and the outlet 38 is disposed in the opposite end, the inlet 
36 is preferably arranged to penetrate both the inner and outer 
walls 22, 32 on the side of the syringe 20. In order to cause the 
most interaction between exhaled air passing through the 
central chamber 24 and the inner surfaces 44 of the inner wall In general, the breath condensate collection devices each 
comprise a collection chamber that has sterile, LPS-free inner 
walls that can be cooled to a temperature below 32° F. to allow 
condensation of exhaled breath. These breath condensate col-
lection devices are preferably disposable and lightweight. 
Each includes coaxial chambers with an interposed area con-
taining coolant that can be chilled externally or via an internal 
endothermic reaction. Such breath condensate collection 
devices are generally described in the aforementioned com-
monly-developed and commonly-assigned U.S. patent appli-
cation Ser. Nos. 10/42,721 and 10/778,477. However, the 
devices described and illustrated herein have additional novel 
and useful features not included in any prior art devices. 
20 22, the inlet 36 is preferably disposed as close to the piston 26 
as possible; however, it will be clear that other arrangements 
of these components are likewise possible without departing 
from the scope of the present invention. 
FIG. 2 is a side cross-sectional schematic view of a breath 
condensate collection device 10 in accordance with a pre-
ferred embodiment of the present invention. This configura-
tion may be particularly appropriate for use with cooperative 
humans. The breath condensate collection device 10 includes 
a double-walled syringe 20 and a breath input assembly 50. 
The inner wall 22 of the syringe 20 defines a cylindrical 
central chamber 24 in which is fitted a plunger assembly 25 
that includes a piston 26, a rubber gasket 28 and a handle 30 
extending from one end of the syringe 20. The outer wall 32 
is arranged around the inner wall 22 in such a way as to create 
The breath input assembly 50 includes a mouthpiece 52, a 
25 filter 54 and any tubing 56 necessary to guide exhaled breath 
from the mouthpiece 52 to the inlet 36 of the syringe 20. The 
mouthpiece 52 is of suitable size and shape so as to permit 
comfortable contact with the mouth area of a patient. The 
filter 54, which may comprise a polymer material having 
30 perforations or successive intrusions therein, may be 
arranged within the tubing 56 between the mouthpiece 52 and 
the syringe inlet 36 to prevent saliva and other liquid or solid 
matter of a minimum size from passing therethrough and into 
the syringe 20. Saliva may be further prevented from reaching 
35 the central chamber 24 by arranging the breath input assem-
bly 50 beneath the syringe 20, so that air passing through the 
breath input assembly 50 moves upward. In this arrangement, 
the effect of gravity on the saliva and other liquid or solid 
matter helps to prevent such matter from passing up into the 
40 central chamber 24, as it instead tends to collect in the tubing 
56. 
The tubing 56 is preferably configured so as to avoid inter-
a narrow space between the inner and outer walls 22, 32. 
During manufacture, the space between the inner and outer 
walls 22, 32 may be filled with a jacket of coolant material 34, 45 
and the outer wall 32 may then be sealed to the inner wall 22 
ference between the mouthpiece 52, or any other part of the 
tubing 56, and the operation of the plunger assembly 25, as 
such operation is described herein. More preferably, the 
mouthpiece 52 is oriented to be generally parallel with the 
syringe 20 and the plunger assembly 25 therein, or in other 
words, the mouthpiece 52 is oriented in parallel to the main 
axis defined by the syringe 20. In this orientation, exhaled 
to prevent leakage. In a preferred embodiment, water may be 
used as the coolant material 34, but it should be clear that 
other materials may likewise be used, such as polyethylene 
glycol ("PEG") and the like. 
The syringe 20 further includes an inlet 36, an outlet 38 and 
50 breath may be received from a patient without causing inter-
ference to the operation of the plunger assembly 25, and 
condensate formed on the inside of the syringe 20 as the 
patient uses the device 10 will tend to drain downward toward 
the outlet 38. 
a pair of one-way valves 40, 42. The first valve 40 is an intake 
valve that may be disposed in or adjacent to the inlet 36, while 
the second valve 42 is an exit valve that may be disposed in or 
adjacent to the outlet 38 in order to facilitate the passage of 55 
exhaled air through the central chamber 24 in only a single 
direction. The outlet 38 is preferably disposed at the end 
opposite the plunger handle 30 in order to permit materials 
collected within the central chamber 24 to be expressed 
through the outlet 38 by the piston 26. The outlet 38 may be 60 
disposed in the end of a nozzle 39 that is in the form of a 
nipple. The nozzle 39 may also include a fitting, such as the 
female portion of a luer lock, at its distal end. Such a fitting 
may permit a protective cover or other accessory to be 
attached to the nozzle 39. The valves 40, 42 are illustrated 65 
only schematically in the various drawings, but they may, for 
example, include two or three self-sealing leaves formed from 
The dimensions of the device 10 are chosen so that a 
sufficient volume of condensate may be collected in a rela-
tively short period of time using a device 10 that is small and 
light enough to be easily held by a patient or attendant and that 
does not require the patient to change his breathing patterns. 
The walls 22, 32 and other structures of the device 10 are 
preferably constructed of a material that tends not to bind to 
proteins, such as platinum-cured silicon. Other suitable mate-
rials may include, but are not limited to, glass, plastic, poly-
ethylene, polycarbonate, or polyvinyl or other synthetic poly-
mer. The plunger assembly 25 is likewise preferably 
constructed from a non-protein-binding material, but may be 
constructed from any suitable inert material including, but not 
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limited to, plastic, vinyl, polyethylene, rubber, platinum-
cured silicon or a fluorine-containing polymer. In addition, 
TEFLON®, which is a fluorine-containing polymer and is a 
registered trademark owned by E.I. Du Pont De Nemours and 
Company Corporation of Wilmington, Del., may be used. In 
a preferred embodiment, the syringe 20 is between 10 and 20 
cm long with a diameter of between 2 and 5 cm. The thickness 
14 
of the coolant jacket 34 may be between 1 and 10 mm, and the 
sample volume, expressed from a single use, is preferably 
between 100 µLand 1000 µL, although it may be possible to 10 
obtain useful results from samples as small as 25 µL. 
surrounding the central chamber 24 is preferably calibrated 
such that the coolant 34 begins to melt after approximately 
10-15 exhalations by the patient. Once the coolant 34 melts or 
thaws after the desired number of exhalations, the condensate 
likewise can begin to melt. Once the condensate is melted, the 
plunger assembly 25 may be depressed to express the col-
lected condensate sample through the outlet 38. 
FIGS. 3A and 3B are partial side cross-sectional schematic 
views of the breath condensate collection device 10 of FIG. 2 
with the plunger assembly 25 in a partially depressed position 
and a fully depressed position, respectively. As the plunger 
assembly 25 is depressed, the needle 35 is forced through the 
outlet 38. Meanwhile, as the volume of the space between the 
The plunger assembly 25 is modified relative to the plunger 
assemblies disclosed in prior applications through the inclu-
sion of the hypodermic needle 35, described previously, or a 
similar structure. This modification facilitates the sterile 15 piston 26 and the outlet 38 shrinks, condensate is forced 
through the radial conduits 31 to the central conduit 33 and delivery of condensate into a specialized reaction chamber 
device, examples of which are described below. The needle 
35 is centrally disposed in the central conduit 33 of the piston 
tip 27, and the interior of the needle 35 is arranged in fluid 
communication with the radial conduits 31 in the tip 27 for a 
purpose made evident hereinbelow. 
In operation, one or more syringes 20 are first stored in a 
refrigeration device, such as a conventional household or 
commercial freezer, that is capable oflowering the tempera-
ture to approximately 0° F., thus freezing the jacket of coolant 
material 34 contained between the inner and outer walls 22, 
32 of the syringe 20. When a patient is to be examined, a 
single syringe 20 is first withdrawn from the freezer. If the 
breath input assembly 50 or mouthpiece 52 is stored sepa-
rately from the rest of the device 10, then the device 10 is 
assembled for use by coupling the various components 
together. Next, the patient positions the mouthpiece 52 in a 
sealed relationship to his mouth area and exhales into the 
mouthpiece 52. The exhaled breath is guided through the 
tubing 56 and into the central chamber 24 via the inlet 36. The 
intake valve 40 is forced open by positive pressure, but in the 
absence of such pressure, it prevents air within the central 
chamber 24 from escaping through the inlet 36. The exhaled 
breath then exits through the outlet 38, on the end of the 
chamber 24 opposite the intake end via the needle 35. The exit 
valve 42 permits air to pass out of the central chamber 24 only 
when positive pressure exists on the cylinder side of the valve 
42, while in the absence of such pressure, the valve 42 pre-
vents ambient air from entering the central chamber 24 via the 
outlet 38. 
As the patient exhales through the device 10, the moisture 
in the exhaled breath begins to condense on the inner surfaces 
44 of the central chamber 24. Because of the depressed tem-
perature of the coolant 34 and the syringe 20, the condensate 
may freeze immediately on the inner surface 44. The diam-
eters of the nozzle 39 and the needle 35 are small enough to 
cause resistance to the exhalation of the patient. The diam-
eters may be preferably chosen so as to slow the rate of 
expiration until each exhalation requires approximately 5 
seconds to complete or until a resistance of up to about 5 cm 
from there into the hypodermic needle 35. The condensate is 
then ready for ejection into a suitable reaction chamber 
device, several examples of which are described below with 
20 reference to FIGS. 7-13. Ejection may be facilitated by com-
plete depression of the plunger assembly 25. A clip assembly 
may be provided at the opposite end of the syringe 20 in order 
to capture the handle 30 of the plunger assembly 25, thereby 
providing an indication to the user that the plunger assembly 
25 25 has been fully depressed. Finally, once the EBC has been 
collected and ejected via the needle 35 in accordance with the 
test procedures described hereinbelow, the entire device 10 
may be disposed of according to conventional waste disposi-
30 tion procedures. 
FIG. 4 is a partial side cross-sectional view of a breath 
condensate collection device 60 in accordance with a second 
preferred embodiment of the present invention. Like the first 
embodiment, this breath condensate collection device 60 
35 includes a double-walled syringe 62, which includes a central 
chamber 24, a plunger assembly 65, a rubber gasket 28 and a 
handle 30, and a breath input assembly (not shown). The body 
of the syringe 62, including the central chamber 24 and the 
various components thereof, are similar to those of the first 
40 syringe 20 with several significant exceptions. First, the outlet 
38 of the first embodiment is replaced with an bleed port 68, 
approximately 1 mm in diameter, penetrating the inner and 
outer walls 22, 32 of the syringe 62 near the distal end thereof. 
The bleed port 68 allows air to escape from the central cham-
45 ber 24 as the plunger assembly is depressed but retains the 
EBC. Also, the plunger assembly 65 does not include a 
nipple-shaped tip on the face of the piston 66 or a needle 
extending therefrom. However, the face of the piston 66 does 
have a slight conical shape, and the end of the central chamber 
50 24 is correspondingly-shaped. Together, this configuration 
may guide collected condensate to the outlet 38 more effi-
ciently. It will be apparent, however, that the nipple-shaped 
tip 27 of the previous device 10 and the conical shape dis-
closed in the device of FIG. 4 are not mutually exclusive, and 
55 that the conical shape may easily be incorporated into the 
device of FIG. 2, i.e, by combining the nipple-shaped tip 27 of 
FIG. 2 with the conical shape of FIG. 4. 
of water pressure is provided. It will be apparent to one of 
ordinary skill in the art that the nozzle 39 may alternatively be 
fitted with a positive end-expiratory pressure valve (a "PEEP" 
valve), which has a dial to vary the resistance to exhalation. 
PEEP valves are commercially available from Life Assist Inc, 60 
Rancho Cordova, Calif. This modification would increase the 
amount of time for exhaled breath to equilibrate with the 
inside surfaces 44 of the central chamber 24. 
Another difference between the first and second devices 
10, 60 is that the second device includes a threaded nozzle 61 
in which may be fixed a hypodermic needle 35. The needle 35 
is similar to the needle 35 of the first device 10, but is fixed in 
the nozzle 61 rather than being mounted on the plunger 
assembly 65. The interior of the needle 35 is communica-
tively connected to the interior of the central chamber 24. The As the patient continues to exhale through the device 10, 
the frozen coolant 34 disposed in the space between the inner 
wall 22 and outer wall 32 of the device 10 begins to melt. The 
composition, volume and thickness of the coolant jacket 34 
65 needle 35 may be protected by a removable plastic covering 
69 having a threaded fitting that facilitates easy connection 
and removal of the covering 69 from the threaded nozzle 61. 
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When attached to the syringe 62, the covering 69 preferably 
provides a relatively air-tight seal for a purpose described 
below. 
Use of this second device 60 is somewhat similar to that of 
the first device 10, although the covering 69 must be removed 
before the subject may breathe through the needle 35. How-
ever, the modifications described above may make this device 
60 better Adapted to deliver a calibrated amount of conden-
sate than the first device 10. Once the subject has taken a 
sufficient number of breaths through the device 60 to ensure 
that a minimum volume of condensate has been collected, the 
covering 69 may be replaced on the end of the syringe 62, and 
the plunger assembly 65 may be carefully depressed. 
Although the covering 69 effectively prevents gas or liquid 
from passing through the needle 35, the bleed port 68, which 
is of conventional design, permits egress of air and any excess 
condensate until the face of the piston 66 passes the calibra-
tion line 78. If desired, a cotton ball or other absorbent mate-
rial, and an appropriate support structure if desired, may be 
disposed over the bleed port 68 in order to prevent EBC from 
escaping to the environment. By holding the device 60 with 
the bleed port 68 oriented in an upward direction, most or all 
16 
mouthpiece or facemask (not shown) into tubing that directs 
flow into the appropriate entry port, such as the ones dia-
grammed in FIG. 2 or FIG. 5. It would also be advantageous 
for the present invention to be adapted to allow collection 
from patients being ventilated mechanically. In most hospi-
tals, humans are ventilated against pressurized air, often 
enriched with oxygen and humidified with excess water 
vapor. This excess water vapor causes condensation to accu-
mulate in the outflow tubing that directs the exhaled breath 
10 away from the patient's lungs during the respiratory cycle. It 
is a standard practice for respiratory therapists to affix a small 
cylinder, of approximately 20-100 mL volume, to collect this 
condensate in the most dependent portion of the exhalation 
circuit. To take advantage of the present invention to diagnose 
15 Gram negative bacterial lung infection in a ventilated patient, 
an aliquot of the collected condensate may be analyzed for 
LPS content. In the simplest embodiment, a commercially 
available syringe of a type used for drug delivery (e.g., an 
insulin syringe) may be used to withdraw a set volume of 
20 condensate (e.g., 100-200 microliters) found in the conden-
sate reservoir in the exhalation line of the ventilation circuit, 
and this volume could be injected into a reaction chamber 
device, examples of which are described hereinbelow. air may be removed from the central chamber 24, and a 
calibrated volume of condensate is left therein as measured by 
the calibration line 78. As shown in FIG. 4, the syringe 62 may 25 
use a single wall design in the region of the calibration line 78 
FIG. 6 is a schematic illustration of an alternative ventila-
tion system implementation of the preferred embodiments of 
the present invention. Using the device 80 of FIG. 5 as an 
example, collection from a ventilated patient may be facili-
tated by adding a vacuum system 92 to the outlet 36 of the 
device 80 and connecting a Y- or T-fitting 94 to the luer lock 
in order to make it easier to see the liquid contained therein. 
Preferably, the syringe 62 is calibrated to collect a volume of 
between 250 and 500 µL. The covering 69 may then be 
removed again and this calibrated volume may be delivered 30 
by the needle 35 into a suitable reaction chamber device. 
fitting, described previously, on the end of the nozzle 39. The 
Y- or T-fitting 94 is connected inline in the middle of the 
outflow path from the patient 96 to a conventional ventilator 
98. The outflow path includes two polyethylene tubes 102, 
104, the first of which is connected from a conventional 
FIG. 5 is a side cross-sectional schematic view of a breath 
condensate collection device 80 in accordance with a third 
preferred embodiment of the present invention. It may be 
advantageous to fractionate exhaled breath into airway and 
alveolar components, to allow condensation to occur only 
from the portion of breath originating from the alveoli. This 
partitioning step may help distinguish lower tract lung infec-
tion from bronchitis. As described in the aforementioned U.S. 
patent application Ser. No. 10/778,477 to Kline, a device for 
collection of exhaled alveolar breath condensate may incor-
porate a gating mechanism actuated, for example, by a rise in 
the partial pressure of exhaled carbon dioxide. The breath 
condensate collection device 80 illustrated in FIG. 5 is an 
example of a device suitable for use in the preferred embodi-
ments of that device or in comparable devices. The device 80 
35 endotracheal tube 100, or other patient interface, to the inlet 
of the Y- or T-fitting 94, and the second of which is connected 
between the outlet of the Y- or T-fitting 94 and a port such as 
the one usually provided on the outflow track of the ventilator 
110. A third polyethylene tube 106, is connected from the 
40 inflow track of the ventilator 110 to the endotracheal tube 100. 
Each polyethylene tube 102, 104, 106 may be of approxi-
mately 10-30 mm internal diameter and 1 meter or more in 
length. Together, such an apparatus allows the vacuum sys-
tem 92 to withdraw a continuous sidestream sample of 
45 exhaled breath through the collection device 80 until a suffi-
cient volume ofEBC is collected. The rate of aspiration by the 
pump of the vacuum system 92 may be set at approximately 
lOOmL/min. 
of FIG. 5 is similar to the device 10 of FIG. 2 except that the 
breath input assembly 50 of the first device 10 has been 
removed to permit the device 80 to be inserted into a housing 
such as that included in the device disclosed in U.S. patent 50 
application Ser. No. 10/778,477. The direction of airflow 
during the condensation process may also be reversed, as 
shown in FIG. 5, either to facilitate fluid communication from 
the gating mechanism or for other purposes, as will be appar-
ent to those of ordinary skill in the art. In this case, the 55 
respective positions of the outlet 36 and inlet 38, and their 
respective one-way valves 81, 83, are now reversed with 
respect to the device 10 of FIG. 2. 
Although not illustrated herein, airflow reversal may also 
FIGS. 7 and 8 are a side cross-sectional schematic view and 
a top view, respectively, of one reaction chamber assembly 
120 suitable for use with the collection devices 10, 60, 80 of 
FIGS. 2, 4 and 5. The reaction chamber assembly 120 is 
designed to detect and quantify the amount ofLPS present in 
the EBC. The assembly 120 resembles the general configu-
ration of a sterile ampule that is commonly used to store drugs 
for injection. The assembly 120 may function both as a reac-
be applied to the device 60 shown in FIG. 4. Even with the 60 
airflow direction reversed, however, the condensate may still 
tion chamber and a spectrophotometer cuvette to measure the 
percentage of transmission of visible light, which is propor-
tional to the concentration ofLPS in the sample. The assem-
bly 120 is vacuum-sealed and includes a reaction chamber 
122 and a plug 124, a retaining ring 126, and a protective cap. 
be delivered into a reaction chamber device via the hypoder-
mic needle 35 as described with regard to either FIGS. 3A and 
3B or FIG. 4. 
In the preceding embodiments, the respective devices 10, 
60, 80 are designed for the collection of EBC from sponta-
neously breathing subjects, where the subject exhales via a 
128. The reaction chamber 122 is preferably made of glass or 
another transparent material, but may alternatively be made 
of a semi-transparent (translucent or other non-opaque) mate-
65 rial if the chosen color or light change or phenomenon, 
described below, may be readily seen therethrough. The reac-
tion chamber 122 preferably has a volume of approximately 
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0.5-1.0 mL. Although as shown the reaction chamber 122 is 
round, it will be apparent that the reaction chamber 122 can 
likewise be square or have another geometric shape to facili-
tate its insertion into a spectrophotometer, or can be altered to 
allow "retrofitting" into existing commercial laboratory assay 
systems. The reaction chamber 122 further includes a 
threaded male luer lock fitting 132 of similar size to that of the 
condensate collection devices 10, 80 described above. Of 
course, if a device 60 such as that disclosed in FIG. 4 is 
utilized, then the luer lock fitting 132 may not be necessary. 
The plug 124, which is preferably formed from rubber, 
may be disposed in the top of the chamber 122 to maintain a 
sealed, sterile, pyrogen-free environment inside the chamber 
122. The plug 124 is retained in the chamber 122 by the 
retaining ring 126, which is preferably formed from alumi-
num and has an opening in the center to permit delivery of 
exhaled breath condensate into the reaction chamber 122 via 
a delivery port 130 in the plug 124. In a preferred embodi-
ment, the delivery port 130 is a re-sealable cover that may be 
punctured with a hypodermic needle. The protective cap 128, 
which is preferably formed from plastic, is temporarily 
attached over the top of the assembly 120 to protect the 
retaining ring 126 and plug 124 from damage or soiling. 
In use, a sterile reaction chamber assembly 120 is retrieved 
from storage, and an EBC sample is collected using one of the 
disclosed devices 10, 60, 80 (or another equivalent device). 
The protective cap 128 of the reaction chamber assembly 120 
is removed and a relatively precise volume of the EBC sample 
is then delivered to the reaction chamber 122 by inserting the 
respective hypodermic needle 35 in the delivery port 130 of 
the plug 124. If provided, the respective luer lock fittings may 
be engaged, effectively locking the device 10, 60, 80 to the 
reaction chamber assembly 120. The plunger assembly 25 
may then be depressed until a sufficient volume of EBC is 
delivered to the assembly 120. A calibration line 134 may be 
marked on the reaction chamber 122 to indicate the necessary 
volume, but if the volume has been pre-calibrated in the 
collection device 60, then such a line 134 may not be neces-
sary. During assembly, the reaction chamber 122 may sealed 
under a vacuum to withdraw a sufficient volume of EBC as 
needed for accurate measurement of endotoxin analyte. 
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chamber. An example of such a salt includes, but is not limited 
to, sodium thiosulfate pentahydrate. Placing the salt within 
the reaction chamber allows introduction of the sampled con-
densate to initiate the exothermic reaction. It is preferred to 
use a powdered salt, which would facilitate immediate and 
complete hydration within a short heating period. For 
example, the salt may be in a semi-permiable matrix or a 
crystalline form that allows controlled hydration to produce a 
reaction temperature of 34-43° C. for at least 15 minutes. 
10 Alternatively, the salt may be disposed in a user-initiated 
heating jacket that surrounds the reaction chamber. In this 
embodiment, the reaction chamber may be inserted into a 
double-walled jacket consisting of a flexible polymer. The 
jacket may contain dry salt capable of liberating heat upon 
15 hydration and an ampule of water (2-5 mL) that can easily be 
ruptured by squeezing with two fingers. The action of ruptur-
ing the ampule of water initiates hydration of the salt, causing 
an exothermic reaction, thus heating the reaction chamber to 
about 43° C. for approximately 15-30 minutes, at which 
20 point, the color intensity and corresponding endotoxin activ-
ity can be quantified as further described herein below. 
Preliminary data suggest that concentrations of LPS 
exceeding approximately 0.20 EU/mL (a calibrated linear 
optical density reading of approximately 0.20) will corre-
25 spond to the clinical test positive threshold, indicating the 
presence of Gram negative bacterial infection in the lungs. In 
the preferred embodiment, the chromogenic substrate may be 
a peptide conjugated to a dye such as para aminoanilde that is 
cleaved by the clotting enzyme to liberate a yellow color to 
30 the reaction solution with peak absorbance at about 405 nm. 
It should be readily understood that other chromogenic sub-
strates could be substituted, and other dye markers could be 
conjugated to the substrate which can be detected at different 
isobestic points. Additionally, the marker molecule may be a 
35 compound that contains the property of excitation fluores-
cence, whereby the molecule liberates light within a narrow 
wavelength interval in response to stimulation by an incident 
beam of monochromatic light. One of ordinary skill in the art 
will understand that various chromogenic and fluorogenic 
40 substrates may be used as markers for detecting the presence 
of the LPS. 
The chamber 122 contains a prespecified dry mass 136 of 
factor C, factor B, proclotting enzyme and chromogenic sub-
strate, together with salts of calcium and magnesium, and 
phosphate salts, or other organic compound, such as TRIS 45 
aminomethane buffer to maintain a pH of approximately 7.4 
upon hydration. The amounts and activities of these enzymes 
are precalibrated to allow detection of a clinically relevant 
range of LPS in the specified volume of EBC. The amounts 
will be calibrated to allow the reaction to produce a linear 50 
optical density reading that ranges from 0 to 1.00 when mea-
sured at 15-30 minutes reaction time at approximately 3 7° C., 
corresponding proportionately to a concentration of LPS 
ranging from 0 to approximately 10 EU/mL in undiluted 
EBC. It is preferred that the temperature of the reaction be 55 
held at least about 34° C. It is more preferred that the tem-
perature of the reaction be held at least about 37° C. 
Alternatively, a reaction chamber assembly may be 
designed to capture LPS using antibodies matrix-bound on 
the sides of the well. FIG. 9 is a perspective view of a first 
alternative reaction chamber assembly 140. In this alternative 
embodiment, the assembly 140 would function as a vertical 
microtiter well employing enzyme-linked immunoassay 
technology and would have the advantage of allowing detec-
tion of species-specific LPS molecules 154. The assembly 
140, which may function as a cuvette, may include a chamber 
142, a plug 144 and a retaining ring or other structure 146. 
Windows 143 are formed in at least a portion of the walls of 
the chamber 142 for a purpose made evident hereinbelow. 
Like the ring 126 of the previous device 120, the ring 146 
includes an opening that exposes an injection target area 150 
in the center of the plug 144. 
FIGS. lOA-lOD are partially schematic, fragmentary side 
The chromogenic substrate can tolerate temperatures up to 
about 43° C. without loss of activity. As such, the reaction 
chamber may be heated by a controlled exothermic reaction 60 
up to about 43° C. It is preferred that the exothermic reaction 
be controlled in order to produce even incubation at 34-43 ° C. 
cross-sectional views of the first alternative reaction chamber 
assembly 140 of FIG. 9. The Fe portion of each antibody 152 
is conjugated or bound to the windows 143 of the assembly 
140 using conventional techniques. The Fab portion of each 
antibody 152 is thus oriented toward the center of the assem-
bly 140 to better capture the 0-polysaccharide portion of the 
LPS 154. After introduction of the EBC sample, the chamber 
for at least 15 minutes, and preferably 25 minutes. Accord-
ingly, and as described hereinbelow, steps should be taken to 
control the rate of the exothermic hydration reaction. 
Such an exothermic reaction may be initiated by placing a 
salt that liberates heat upon hydration within the reaction 
65 142 may then be washed with an albumin-containing buffer 
(not shown) to remove nonspecific materials. Then, a separate 
ampule, containing a prespecified amount of chromogenic 
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and reaction chamber 208 are connected by the first microtu-
bule 214, while the reaction chamber 208 is connected to the 
outlet 222 by the second microtubule 216. One of ordinary 
skill in the art will understand that microtubule 214 may 
include one or more microtubules. Valves 218, 220 are dis-
posed in the first and second microtubules 214, 216, respec-
tively, so as to facilitate one-way fluid communication from 
the port 204 through the reaction chamber 208 to the outlet 
222. If microtubule 214 includes a plurality of microtubules, 
substrates 156, such as those described previously, is recon-
stituted by adding LPS-free water (not shown), and the chro-
mogenic reagent sample is withdrawn by syringe and injected 
into the reaction chamber 142, as shown in FIG. lOC. The 
chromogenic substrates 156 react with the LPS 154, thereby 
liberating a dye 158. After approximately 15-30 minutes, 
optical density may be read by one of several methods. One 
chromogenic substrate 156 suitable for use in the preferred 
embodiments of the present invention incorporates para 
nitroanilide, which when freed can be detected at about 405-
410 nm. 
It will be apparent to those of ordinary skill in the art that 
rather than an antibody with specific immunogenicity toward 
0-antigen, other molecules with specific and high affinity for 
any portion ofLPS may be bound to the walls of the reaction 
chamber for capture ofLPS. These molecules include, but are 
not limited to, HA-IA and E5, lipopolysaccharide binding 
protein ("LPB"), bacteriocidal/permeability increasing pro-
tein ("BPI"); limulus anti-lipopolysaccharide factor 
("LALF") or the polymyxin antibiotics. 
10 more than one valve 218, 220 may be necessary to accom-
modate the plurality of microtubules. The top of the cartridge 
has a preprinted color strip 221 with a series of successively 
darker color patches disposed thereon and arranged such that 
each successively darker color patch corresponds to an incre-
15 mentally greater interval of endotoxin activity. 
The chamber 208 is covered with a clear material 210 to 
allow viewing of the matrix 212 for color change indicating 
the presence ofLPS. The matrix 212, which is arranged in the 
chamber 208, is a surface formed from an insoluble polymer 
20 or other material that will accept and be stained by the chro-
mogenic substrate. Suitable materials include, but are not 
limited to, polymers derived from cellulose, agarose, meth-
acrylate, polystyrene, polyphenyl, polynaphthyl, polybenzyl, 
In order to quantify LPS concentration, a number of 
embodiments may be utilized. In one embodiment, a semi-
quantitative determination may be made using a visual com-
parison to a color strip. The color strip may resemble a stan-
dard ruler having patches of one color displayed left to right 25 
in incrementally increasing degrees of shade intensity, with 
the lightest shade being located furthest left and the darkest 
shade being located furthest right. Each shade patch is asso-
ciated with a specific range of endotoxin unit (EU) reactivity 
with increasing degrees of shade intensity signifying increas- 30 
ing EU reactivity. An observer may hold the clear reaction 
chamber assembly 120, 140 in ambient light next to the plas-
tic or paper color strip for comparing the shade of the contents 
nylon, silk or other fabric and the like. The matrix 212 is 
absorbent but tightly woven such that it permits fluid to 
remain suspended in the chamber 208 until the fluid moves by 
gravity and capillary action through microtubule 216. As an 
advantage, the matrix 212 may intrinsically bind LPS itself or 
may covalently or otherwise bind one of the LPS-binding 
molecules, such as HA-IA and E5, LPB, BPI, LALF or the 
polymyxin antibiotics. The matrix 212, therefore, develops a 
color intensity in proportion to the concentration of endotoxin 
in the unknown sample. Visual comparison to the pre-printed 
color-strip 221 allows a semi-quantitative determination of 
endotoxin concentration, as described above. 
The interior of the test kit 200 may also contain sodium 
thiosulfate pentahydrate and a sealed ampule of water that 
ruptures upon squeezing of the test kit 200. The action of 
rupturing the ampule of water will initiate hydration of the 
of the reaction chamber assembly 120, 140 with the color 
strip patches. The observer may then select the color patch 35 
that best matches the color shade intensity observed in the 
reaction chamber. A positive reaction would be indicated by a 
specific color shade threshold, corresponding to approxi-
mately 0.20 EU/mL or as determined from additional experi-
ments. 40 sodium thiosulfate, causing an exothermic reaction, thus 
heating the entire test kit 200 to about 43° C. for approxi-
mately 25 minutes. Although the materials for the exothermic 
reaction are disposed within the test kit 200, they are sepa-
More precise quantification may be obtained with a small, 
specially designed single beam light spectrophotometer that 
is configured to accept the reaction chamber after incubation 
as described above. The spectrophotometer may contain a 
heating coil that is activated upon insertion of the reaction 45 
chamber to warm the sample to 3 7° F. The spectrophotometer 
may alternatively display or print the measure optical density 
after 25 minutes of incubation. 
FIG. 11 is a perspective view of a test kit 200 incorporating 
rated from all areas of the test kit 200 in which the sample is 
introduced and in which any LPS-related chemical reactions 
occur. 
In operation, the reaction is initiated by injecting conden-
sate collected with device 10, 60, 80 into the chamber 204 that 
contains the dry mass 136 described previously. It is preferred 
a second alternative reaction chamber device, which would 
allow EBC to be delivered to a single-use cartridge that could 
50 that at least about 0.35 mL of condensate be injected into the 
reaction chamber 204. The action of injecting the condensate 
causes a mixing action of the condensate and dry mass 136 in 
the reaction chamber 204 and the microtubule 214, thereby 
initiating the LAL reaction. The pressure differential induced 
be read visually without the use of a spectrophotometer. The 
test kit 200 has two modules 203, 223, including a test module 
203 and a positive control module 223, arranged in a housing 
202. FIG. 12 is a side cross-sectional view of the test module 
203 of FIG. 11, taken along line 12-12. The test module 203 
includes a port 204. Port 204 preferably has a volume of 
approximately I 00 micro liters and contains dry mass 136 of 
factor C, factor B, proclotting enzyme and chromogenic sub-
strate, together with EDTA, salts of calcium and magnesium, 60 
and phosphate salts, or other organic compound, which 
allows the dry mass to maintain a pH of approximately 7.4 
upon hydration and to form an aqueous reagent. 
55 by injection, coupled with the force of capillary action causes 
the reaction mixture to flow down microtubule 214 into the 
FIG.11 further shows a reaction chamber 208, a test matrix 
212, a pairofmicrotubules 214, 216, a pairofone-wayvalves 65 
218, 220 and an outlet 222. Reaction chamber 208 preferably 
has a volume of at least about 250 microliters. The port 204 
reaction chamber 208, where it remains while the chromoge-
nic reaction continues at a temperature of 34-43° C. Since 
endotoxin will be bound to the matrix 212, the colored mol-
ecule that is hydrolyzed from the chromogenic substrate will 
stain the matrix 212 in a color hue intensity that is propor-
tional to the activity of endotoxin in the condensate, the color 
change can be visually compared with the color strip 221 for 
quantitation. 
FIG.13 is a side cross-sectional view of the positive control 
module 223 of FIG. 11, taken along line 13-13. The positive 
control module 223 includes a port 224; a reaction chamber 
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228; a test matrix 232; a quantity of dry LPS combined with 
dry mass 136, represented herein as 244; a pair of microtu-
bules 234, 236; a pair of one-way valves 238, 240 and an 
outlet 242. The port 224 and reaction chamber 228 are con-
nected by the first microtubule 234, and the reaction chamber 
228 is connected to the outlet 242 by the second microtubule 
236. The valves 238, 240 are disposed in the first and second 
microtubules 234, 236, respectively, so as to permit one-way 
fluid communication from the port 224 through the reaction 
chamber 228 to the outlet 242. As illustrated, the LPS 244 is 10 
disposed in the port 224, but it will be apparent that the LPS 
244 may alternatively or additionally be disposed in the first 
microtubule 234 or on the test matrix 232. 
The second alternative reaction chamber device may also 
22 
that the syringe 262 further includes a manometer 265 extend-
ing from the side of the syringe in fluid communication with 
the outlet 68. In addition, although each device 60, 260 
includes a needle 35, 275, the needle 275 of this fourth 
embodiment serves as the narrow tube in which EBC is con-
tacted with the LAL assay reagent. Accordingly, the needle 
275 is plugged with a dry, insoluble and inert fiber matrix 270, 
as shown in FIG. 15, which is preloaded with the LAL assay 
reagent for gelation if LPS is present in the EBC. 
A reaction may be initiated by depressing the plunger 
assembly 65 until the plug 270 is wetted with EBC. The 
amount of gelation in the outflow needle 275 will be propor-
tional to the amount of LPS in the EBC. After a specified 
period of time, the plunger assembly 65 may be forcibly 
be used as follows. An EBC sample is injected from one of the 
previously-described breath condensate collection devicees 
10, 60, 80 into the test module port 204, from where it may be 
directed via the first test module microtubule 214 to the test 
module reaction chamber 208. In a preferred embodiment, 
the volume of the EBC sample is about 0.35 mL. The volume 
15 depressed again, and the extrusion pressure measured within 
the central chamber 24 using the manometer 265. The extru-
sion pressure is proportional to the LPS concentration in the 
EBC. 
In all of the preceding embodiments, it should be recog-
20 nized that the specificity of the reaction can be enhanced by 
inclusion of chemicals or methods to prevent reaction with 
beta glucans (factor G), including heating the sample to 75° 
C., adding alkylglucosides, or molecules with beta 1,4 glu-
of the sample is preferably calibrated such that the well 208 
containing the matrix 212 fills to capacity, thus covering the 
matrix 212 with liquid and initiating LPS binding to the 
matrix 212. Excess EBC may flow out through the second test 
module microtubule 216. The one-way valve 218 prevents 25 
entry of LPS from ambient air. Absorbent material may be 
placed in 216 to prevent any external fluid leak. 
After a relatively precise predetermined period of time, 
which may be about 60 seconds, the test module 203 and the 
positive control module 223 may each be washed with a 
quantity of sterile (endotoxin-free) water. In a preferred 
embodiment, the volume of sterile water that is injected into 
each module 203, 223 is about 0.25 mL. The water passes 
through the respective reaction chambers 208, 228 and is 
allowed to drain through the respective outlets 222, 242 via 
the respective second microtubule 216, 236. 
Next, LPS-free water is added to an ampule, such as the 
reaction chamber device 120 of FIGS. 7 and 8, containing a 
dry mass 136 of factor C, factor B, proclotting enzyme and 
chromogenic substrate, together with EDTA, salts of calcium 
and magnesium, and phosphate salts, or other organic com-
pound to maintain a pH of approximately 7.4 upon hydration 
to form an aqueous reagent. Once the reagent is reconstituted, 
cosidic linkages. 
Once a Gram negative bacterial infection is diagnosed, 
antibiotic therapy may begin. Those skilled in the art will 
understand that the method of the present invention may be 
utilized to monitor the effectiveness of antibiotic therapy. It 
can be predicted by those skilled in the art, that effective 
30 antibiotic therapy may cause an initial increase in LPS con-
centration in expired breath condensate, owing to bacterial 
demise with cell membrane rupture and increased release of 
free LPS into alveolar epithelial fluid. This concentration 
increase would be expected in the first 24 to 72 hours after 
35 antibiotic administration. It could further be predicted that 
effective antibiotic therapy would eventually cause a decrease 
in the concentration ofLPS in expired breath condensate over 
the subsequent 3-10 days after antibiotic administration. 
Accordingly, it can be surmised that serial LPS measurements 
40 may be used to monitor treatment efficacy. A failure to exhibit 
an initial increase in expired LPS content or a failure to 
exhibit a decline in expired LPS content in the subsequent 
days could signal resistance of the Gram negative bacteria to 
it may be withdrawn using a syringe such as that commonly 
used to deliver insulin or to provide tuberculosis testing anti- 45 
gen (often referred to as a "TB syringe") (not shown) and 
injected into both the test module port 204 and the positive 
control module port 224. The test kit 200 may then be left to 
develop for a prespecified time interval, e.g., 10 minutes at 
treatment. 
The present invention is advantageous because it provides 
a method and device for diagnosing a Gram negative bacterial 
infection in a relatively easy, painless and quick manner. The 
present application is directed to diagnosing Gram negative 
bacterial pneumonia by measuring the concentration of LPS 
in exhaled breath condensate. However, the present invention 
may also be utilized to diagnose any intrapulmonary Gram 
23 ° C., and then visually inspected for color or pattern change 50 
in the test well 208. The positive control module 223 is 
included to ensure activity of the chromogenic enzyme sys-
tem. 
negative bacterial infection, including, but not limited to, 
septicemia. One of ordinary skill in the art will understand 
that Gram negative bacterial infections may be treated with In a still further alternative, the proportion ofLPS in EBC 
could be measured by allowing gel formation of the clotting 
cascade within a narrow tube, as described in Neeman et al., 
U.S. Pat. No. 4,370,413, (the '413 patent), the entirety of 
which is incorporated herein by reference. FIG. 14 is a partial 
side cross-sectional view of a breath condensate collection 
device 260 in accordance with a fourth preferred embodiment 
55 the same antibiotic treatment and thus diagnoses of any Gram 
negative bacterial infection is beneficial for a subject suffer-
ing from such infection. Further, the present invention may 
also be utilized to identify a specific strain of Gram negative 
bacteria causing infection in a situation in which this infor-
60 mation may be beneficial. 
of the present invention. This device 260 is similar to that of 
FIG. 4, in that it includes a syringe 262 having double walls 
22, 32, a central chamber 24, a plunger assembly 65 with a 
piston 26, a rubber gasket 28 and a handle 30, a breath input 
assembly (not shown), an outlet 68, a threaded nozzle 61, and 65 
a removable plastic covering 69. Each of these components is 
generally similar to those of the device 60 of FIG. 4, except 
EXAMPLES 
Example 1 
LPS was detected in exhaled breath condensate samples 
from subjects that were awake, cooperative and able to 
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breathe spontaneously in order to diagnose whether such 
subjects had Gram negative bacterial pneumonia according to 
the following procedure. 
The subjects for the procedure were selected according to 
the following procedure. Subjects (N=S per group) were 
recruited based upon three criteria: 1) diagnosis of pneumo-
nia, 2) healthy patients who actively smoked more than 10 
cigarettes per day and 3) healthy nonsmokers. To obtain sub-
jects diagnosed with pneumonia, subjects diagnosed on stan-
dard clinical grounds, including cough productive of colored 10 
sputum, measured fever> 101° F., a leukocytosis, evidenced 
by a peripheral total white blood count of>12,000 cells per 
cubic microliter, and the presence of an infiltrate on chest 
radiograph were selected. Exclusion criteria for subjects 
included any use of antimicrobial medications, acute illness 15 
or anatomical abnormality that precluded breath collection 
and/or suspected pulmonary tuberculosis. 
The breath condensing device utilized for collected 
exhaled breath samples is described as follows. The device 
consisted of a one-meter long polyvinyl tube (15 mm ID) 20 
attached to a modified glass flask, which was approximately 
50 cm in height. The glass flask had a specially designed, 
removable glass stopper at the top but was otherwise similar 
in appearance to a standard laboratory volumetric (Florence) 
flask. The glass stopper had two ports, one for entry of a glass 25 
tube that projected upward and was bent at a 90° angle and 
another to allow dried, exhaled air to exit into ambient air. 
One end of the glass tube was connected to a polyvinyl tube 
that fit snugly over the glass tube. The other end of the glass 
tube projected into the interior of the glass bulb of the flask by 30 
approximately 25 cm. The entire glass flask was submerged in 
a cooling slurry of frozen carbon dioxide in ethanol. 
Exhaled breath condensate was collected according to the 
following procedure. A subject was allowed to hold the poly-
vinyl tube and breath into a duckbill-shaped mouthpiece that 35 
was attached to the opposite end of the polyvinyl tube. The 
subject's breath passed through the polyvinyl tube into the 
condenser chamber of the flask, where the cooled inner side 
of the flask would condense and freeze the expired water 
vapor and aerosolized droplets in the subject's breath. Sub- 40 
jects were asked to deliver approximately 30 deep exhala-
tions, which yielded approximately 1-3 mL of sample. 
Prior to collection of breath samples from subjects, mul-
tiple steps were take to reduce sample contamination with 
extraneous endotoxin or beta glucan molecules. All compo- 45 
nents were sterilized by autoclaving at 220° C. for a minimum 
24 
thawed condensate using a chromogenic limulus assay 
according to manufacturer's specifications (Pyrochrome 
Assay, Associates of Cape Cod, Falmouth, Mass., USA). 
Reactions were carried out on 96-well microtitre plates (Py-
rochrome microtitre plates, Associates of Cape Cod) at 3 7° C. 
for 30 min, and the color change read with a microtitre plate 
spectrophotometer at 405 nm. All samples were run during 
one batch. The standard curve was performed using the assay 
endotoxin standard and was linear with R=0.997. 
FIG. 16 is a scatter plot graph illustrating the measured 
endotoxin concentrations for patients in each of three study 
groups. The mean (±SD) endotoxin concentration in normals, 
smokers, and patients with pneumonia was 0.096±0.050, 
0.091±0.040, and 0.234±0.130 EU/mL, respectively. The 
plot suggests that 0.20 EU/mL may be a useful cutoff point to 
distinguish subjects with Gram negative pneumonia from 
subjects without Gram negative pneumonia. 
Two subjects with pneumonia and test values below 0.20 
EU/mL are labeled "A" and "B". Traditional clinical tests 
confirmed that these subjects did not have Gram negative 
bacterial pneumonia. Patient A had blood cultures that were 
positive for streptococcus pneumonia, which was clinically 
presumed to be the bacterial cause of the patient's pneumo-
nia; patient B had clinically suspected influenza! (viral) pneu-
monia with negative blood cultures and no other specimens 
submitted for analysis. 
Two of the water samples from the mock standard had 
values of0.10 and0.14 EU/mL (mean0.12 EU/mL).Accord-
ingly, 0.12 EU/mL was considered the background "noise" of 
the system, and this value was subtracted from the cutoff 
value of 0.20 EU/mL determined in uncorrected samples. 
Using this analysis, a sample of expired breath condensate 
containing a value above 0.08 EU/mL would be considered an 
abnormal test result. It should be recognized that this back-
ground correction value may differ if a different condenser 
apparatus is used in another laboratory. 
Example 2 
LPS was detected in exhaled breath condensate samples 
from subjects that were breathing with the assistance of a 
ventilator in order to diagnose whether such subjects had 
Gram negative bacterial pneumonia according to the follow-
ing procedure. 
Six subjects participated in the study. Four of the ventilated 
subjects presented clinical evidence of pneumonia and were 
being treated with antibiotic therapy, and two of the ventilated 
subjects presented no clinical evidence of pneumonia and 
were used as controls. 
Breath condensate samples were obtained according to the 
following procedure. The analyte was obtained from the 
exhaled breath condensate that accumulated in outflow tubing 
attached to the endotracheal tube of the ventilation system. 
Analyte appeared clear and non-turbid upon visual inspec-
tion. 
The presence of endotoxin was detected according to the 
following procedure. An assay was performed on undiluted 
and diluted condensate using a chromogenic limulus assay 
according to manufacturer's specifications (Pyrochrome 
Assay, Associates of Cape Cod, Falmouth, Mass., USA). The 
dilutions included 1: 10, 1: 100and1:1000 dilutions in endot-
oxin-free water. Reactions were carried out on 96-well 
microtitre plates (Pyrochrome microtitre plates, Associates of 
Cape Cod) at 3 7° C. for 30 minutes, and the color change read 
of 4 hours between uses and by using a commercially avail-
able washing solution designed to remove endotoxin. The 
polyvinyl tube was wrapped in sterile foil prior to autoclav-
ing. The sterile foil was left in place during sample collection 50 
but was removed prior to removing the polyvinyl tube. The 
technician used sterile gloves to handle all components. How-
ever, the terminal 6 cm of the polyvinyl tube was able to be 
grasped by the subject, who did not wear sterile gloves. After 
the condensate was allowed to melt, it was aspirated from the 55 
condenser chamber with pyrogen-free pipette tips and trans-
ferred to pyrogen-free cryotubes under a laminar hood. To 
examine for background endotoxin, a "mock" standard of the 
glassware and tubing was conducted according to the follow-
ing procedure. Two milliliters of endotoxin-free water 60 
(Sigma Chemical, St. Louis, Mo.) was instilled into the 
washed, autoclaved condenser chamber, agitated and then 
aspirated and stored in the same manner as the condensate 
samples. Condensate samples and the water run for a mock 
standard were stored at -57° C. until assay. 65 with a microtitre plate spectrophotometer at 405 nm. All 
samples were run during one batch. The upper limit of detec-
tion of the assay was 0.25 EU/mL. 
The presence of endotoxin was detected according to the 
following procedure. An assay was performed on undiluted, 
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The results of the assay are as follows.All six samples were 
above limits of detection in the undiluted samples (i.e., 
greater than 0.25 EU/mL). The mean endotoxin concentra-
tion in all the 1: 10 dilution samples of subjects with pneumo-
nia was above the limit of linear detection, but the mean 
endotoxin concentration from the two ventilated patients 
without pneumonia in the 1: 10 dilutions was <0.05 EU/mL. 
These data suggest that the presence of more than 0.25 
EU/mL in samples of condensate in the outflow tubing of a 
ventilator circuit that appear clear and non-turbid upon visual 10 
inspection would predict the presence of a bronchoalveolar 
lavage sample that would be positive for gram negative pneu-
moma. 
Example 3 15 
LPS was detected in exhaled breath condensate according 
to the following procedure. A commercially available I-liter 
volume glass flask was prepared for collecting breath con-
densate samples according to the following procedure. The 20 
glass was heated to 400° C. for 3 hours to render its surfaces 
LPS-free. A sterilized, flexible polyvinyl tube, 11 mm in 
internal diameter, was arranged in fluid communication to a 
side-arm of the flask such that when a patient breathed into the 
tube, the patient's breath passed through the glass flask and 25 
out through an exit port. The flask was partially submerged in 
a dry ice and ethanol slurry mixture as a coolant to facilitate 
capture of exhaled breath condensate in the flask. The tube 
and flask were arranged in a fashion to keep the condensing 
flask above the level of the patient to prevent any capture of 30 
aerosolized saliva. 
Exhaled breath was collected according to the following 
procedure. Eight subjects of varying health status breathed 
into the tube connected to the flask. Each subject breathed 100 
deep exhalations into the flask, using a hand counter to keep 35 
track of breaths. This method provided a mean volume of 
condensate equal to 11 ±4 mL. 
A chromogenic commercial LAL assay (Cape Cod, Mass.) 
was used to detect LPS in the exhaled breath condensate 
according to the following procedure. From each subject's 40 
condensate sample, duplicate 50 µL aliquots were transferred 
into two wells of a standard 96-well ELISA plate. The 
reagents required forthe chromogenic LAL assay were added 
and the samples were incubated for 30 minutes at 37° C. The 
optical density was read at 405 nm in a commercially avail- 45 
able plate well reader. Concentrations were determined by 
comparison to a standard curve using known amounts ofLPS 
obtained from a FDA-certified source. 
Results were obtained as follows. Four normal volunteers 
were all found to have concentrations of LPS below 100 50 
pg/mL, whereas two otherwise healthy smokers were found 
to have concentrations below 200 pg/mL. Two smokers with 
clinical pneumonia were found to have EBC LPS concentra-
tions above 800 pg/mL. From this experiment, it was con-
cluded that LPS content ofEBC samples can vary based upon 55 
the health of the lung in the subjects providing the samples. 
These data also suggest that EBC can be sampled without 
contamination from oral flora in healthy subjects. 
Based on the foregoing information, it is readily under-
stood by those persons skilled in the art that the present 60 
invention is susceptible of broad utility and application. Many 
embodiments and adaptations of the present invention other 
than those specifically described herein, as well as many 
variations, modifications, and equivalent arrangements, will 
be apparent from or reasonably suggested by the present 65 
invention and the foregoing descriptions thereof, without 
departing from the substance or scope of the present inven-
26 
tion. Accordingly, while the present invention has been 
described herein in detail in relation to its preferred embodi-
ment, it is to be understood that this disclosure is only illus-
trative and exemplary of the present invention and is made 
merely for the purpose of providing a full and enabling dis-
closure of the invention. The foregoing disclosure is not 
intended to be construed to limit the present invention or 
otherwise exclude any such other embodiments, adaptations, 
variations, modifications or equivalent arrangements; the 
present invention being limited only by the claims appended 
hereto and the equivalents thereof. Although specific terms 
are employed herein, they are used in a generic and descrip-
tive sense only and not for the purpose of limitation. 
What is claimed is: 
1. A method for diagnosing and monitoring intrapulmo-
nary Gram negative bacterial infection in an air-breathing 
vertebrate subject, comprising: 
(a) collecting exhaled breath condensate from an air-
breathing vertebrate subject; 
(b) providing a reaction chamber with an interior surface, 
wherein said reaction chamber has a material that binds 
lipopolysaccharide disposed therein; 
( c) delivering at least a portion of the collected breath 
condensate to the reaction chamber; 
( d) washing the reaction chamber with a buffer; 
( e) delivering a reaction reagent to the reaction chamber; 
(f) determining whether the subject has an intrapulmonary 
Gram negative bacterial infection based on a physical 
change that occurs when the at least a portion of the 
collected exhaled breath condensate is delivered to the 
reaction chamber, wherein said physical change is 
caused by the presence of lipopolysaccharide in the 
exhaled breath condensate, and 
(g) identifying the particular strain of the intrapulmonary 
Gram negative bacteria; 
wherein identifying includes identifying the particular 
strain of intrapulmonary Gram negative bacteria based 
upon a determination of the 0-antigen portion of the 
lipopolysaccharide molecule, 
wherein the binding material is embedded in a matrix 
surface disposed within the reaction chamber. 
2. A method for diagnosing and monitoring intrapulmo-
nary Gram negative bacterial infection in an air-breathing 
vertebrate subject, comprising: 
collecting exhaled breath condensate from the air-breath-
ing vertebrate subject; 
providing a reaction chamber, wherein said reaction cham-
ber has a reaction reagent disposed therein; 
delivering at least a portion of the collected exhaled breath 
condensate to the reaction chamber; 
determining whether the subject has an intrapulmonary 
Gram negative bacterial infection based on a physical 
change that occurs when at least a portion of the col-
lected exhaled breath condensate is delivered to the reac-
tion chamber, wherein said physical change is caused by 
the presence oflipopolysaccharide in the exhaled breath 
condensate; and 
identifying the particular strain of the intrapulmonary 
Gram negative bacteria; 
wherein identifying includes identifying the particular strain 
ofintrapulmonary Gram negative bacteria based upon a deter-
mination of the 0-antigen portion of the lipopolysaccharide 
molecule. 
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3. A method for diagnosing and monitoring intrapulmo-
nary Gram negative bacterial infection in an air-breathing 
vertebrate subject, comprising: 
collecting exhaled breath condensate from an air-breathing 
vertebrate subject; 
providing a reaction chamber, wherein said reaction cham-
ber has a reaction reagent disposed therein; 
delivering at least a portion of the collected exhaled breath 
condensate to the reaction chamber; 
determining whether the subject has an intrapulmonary 10 
Gram negative bacterial infection based on a physical 
change that occurs when the at least a portion of the 
collected exhaled breath condensate is delivered to the 
reaction chamber, wherein said physical change is 
caused by the presence of lipopolysaccharide in the 15 
exhaled breath condensate; 
visually matching a color change in the reaction chamber 
to a standard, wherein said standard comprises a printed 
strip of color patches of increasing hue intensity, and 
wherein each color patch corresponds to increasing con- 20 
centrations of lipopolysaccharide, respectively, and 
identifying the particular strain of the intrapulmonary 
Gram negative bacteria; 
wherein identifying includes identifying the particular strain 
ofintrapulmonary Gram negative bacteria based upon a deter- 25 
mination of the 0-antigen portion of the lipopolysaccharide 
molecule. 
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4. A method for diagnosing and monitoring intrapulmo-
nary Gram negative bacterial infection in an air-breathing 
vertebrate subject, comprising: 
collecting exhaled breath condensate from an air-breathing 
vertebrate subject; 
providing a reaction chamber with an interior surface, 
wherein said reaction chamber contains a material that 
binds lipopolysaccharide disposed therein; 
delivering at least a portion of the collected breath conden-
sate to the reaction chamber; 
washing the reaction chamber with a buffer; 
delivering a reaction reagent to the reaction chamber; and 
determining whether the subject has an intrapulmonary 
Gram negative bacterial infection based on a physical 
change that occurs when the at least a portion of the 
collected exhaled breath condensate is delivered to the 
reaction chamber, wherein said physical change is 
caused by the presence of lipopolysaccharide in the 
exhaled breath condensate, and 
identifying the particular strain of the intrapulmonary 
Gram negative bacteria; 
wherein identifying includes identifying the particular strain 
ofintrapulmonary Gram negative bacteria based upon a deter-
mination of the 0-antigen portion of the lipopolysaccharide 
molecule. 
* * * * * 
